{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T12:09:32Z","timestamp":1664885372578},"reference-count":44,"publisher":"Walter de Gruyter GmbH","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Modern medical and technological advances provide highly effective management for the treatment of patients with heart failure with reduced ejection fraction (HFrEF). In this review, the authors propose a 2-step approach to treatment that is straightforward, practical, and thorough. For the patient whose life now includes HFrEF, the physician's first step is to ensure that the patient is taking the 3 key medications ([1] renin-angiotensin inhibitors (angiotensin receptor\/neprilysin inhibitors, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers), [2] \u03b2-blockers, and [3] mineralocorticoid receptor antagonists) recommended in guideline-directed doses to attain comprehensive receptor blockade. Significant coexisting medical issues are also characteristic in patients with HFrEF. Therefore, the physician's second step is to address the comorbidities of heart failure to fulfill comprehensive patient care. This review presents evidence to implement the management of HFrEF and heart failure comorbidities that will reduce cardiac mortality and hospitalization and to avoid treatments that are of no benefit or may cause harm.<\/jats:p>","DOI":"10.7556\/jaoa.2020.007","type":"journal-article","created":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T16:30:50Z","timestamp":1580142650000},"page":"90-99","source":"Crossref","is-referenced-by-count":1,"title":["A Stepwise Approach to the Management of Heart Failure and its Comorbidities"],"prefix":"10.1515","volume":"120","author":[{"given":"Felix J.","family":"Rogers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeinab","family":"Saghir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2020,2,1]]},"reference":[{"issue":"128","key":"2021032622392042935_j_jaoa.2020.007_ref_001_w2aab3b7c33b1b6b1ab2b1b1Aa","doi-asserted-by":"publisher","first-page":"e240","DOI":"10.1161\/CIR.0b013e31829e8776","article-title":"ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"2013","year":"2013","journal-title":"Circulation"},{"issue":"134","key":"2021032622392042935_j_jaoa.2020.007_ref_002_w2aab3b7c33b1b6b1ab2b1b2Aa","doi-asserted-by":"publisher","first-page":"e282","DOI":"10.1161\/CIR.0000000000000435","article-title":"ACC\/AHA\/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF\/AHA Guideline for the management of heart failure","volume":"2016","year":"2016","journal-title":"Circulation"},{"issue":"70","key":"2021032622392042935_j_jaoa.2020.007_ref_003_w2aab3b7c33b1b6b1ab2b1b3Aa","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","article-title":"ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines and the Heart Failure Society of America","volume":"2017","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"2021032622392042935_j_jaoa.2020.007_ref_004_w2aab3b7c33b1b6b1ab2b1b4Aa","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1016\/j.jacc.2017.11.025","article-title":"ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Task Force on expert consensus decision pathways [published correction appears","volume":"72","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"133","key":"2021032622392042935_j_jaoa.2020.007_ref_005_w2aab3b7c33b1b6b1ab2b1b5Aa","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1161\/CIR.0000000000000350","article-title":"Heart disease and stroke statistics-2016 update: a report from the American Heart Association.","volume":"2016","journal-title":"Circulation"},{"key":"2021032622392042935_j_jaoa.2020.007_ref_006_w2aab3b7c33b1b6b1ab2b1b6Aa","volume-title":"The Checklist Manifesto: How to Get Things Right","year":"2010"},{"issue":"4","key":"2021032622392042935_j_jaoa.2020.007_ref_007_w2aab3b7c33b1b6b1ab2b1b7Aa","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF Registry","volume":"72","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"2021032622392042935_j_jaoa.2020.007_ref_008_w2aab3b7c33b1b6b1ab2b1b8Aa","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.jacc.2018.11.049","article-title":"Clinical course of patients with worsening heart failure with reduced ejection fraction","volume":"73","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2021032622392042935_j_jaoa.2020.007_ref_009_w2aab3b7c33b1b6b1ab2b1b9Aa","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"2021032622392042935_j_jaoa.2020.007_ref_010_w2aab3b7c33b1b6b1ab2b1c10Aa","doi-asserted-by":"publisher","first-page":"e004302","DOI":"10.1161\/CIRCHEARTFAILURE","article-title":"Adoption of sacubitril\/valsartan for the management of patients with heart failure","volume":"11","year":"2018","journal-title":"Circ Heart Fail"},{"issue":"1","key":"2021032622392042935_j_jaoa.2020.007_ref_011_w2aab3b7c33b1b6b1ab2b1c11Aa","doi-asserted-by":"publisher","first-page":"e005171","DOI":"10.1161\/CIRCHEARTFAILURE.118.005171","article-title":"Characteristics of acute heart failure hospitalizations based on presenting severity","volume":"12","year":"2019","journal-title":"Circ Heart Fail"},{"key":"2021032622392042935_j_jaoa.2020.007_ref_012_w2aab3b7c33b1b6b1ab2b1c12Aa","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1093\/eurheartj\/ehv134","article-title":"Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes","volume":"36","year":"2015","journal-title":"Eur Heart J"},{"issue":"22","key":"2021032622392042935_j_jaoa.2020.007_ref_013_w2aab3b7c33b1b6b1ab2b1c13Aa","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1016\/j.jacc.2018.02.078","article-title":"Prevention of heart failure with SGLT-2 inhibition: insights from CVD-REAL","volume":"71","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"2021032622392042935_j_jaoa.2020.007_ref_014_w2aab3b7c33b1b6b1ab2b1c14Aa","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1016\/j.jacc.2018.03.009","article-title":"Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD REAL 2 study","volume":"71","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"2021032622392042935_j_jaoa.2020.007_ref_015_w2aab3b7c33b1b6b1ab2b1c15Aa","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"2021032622392042935_j_jaoa.2020.007_ref_016_w2aab3b7c33b1b6b1ab2b1c16Aa","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.jchf.2018.05.020","article-title":"Antihyperglycemic therapies to treat patients with heart failure and diabetes mellitus","volume":"6","year":"2018","journal-title":"JACC Heart Fail"},{"issue":"6","key":"2021032622392042935_j_jaoa.2020.007_ref_017_w2aab3b7c33b1b6b1ab2b1c17Aa","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jchf.2017.12.016","article-title":"Worsening heart failure during the use of DPP-4 inhibitors: pathophysiological mechanisms, clinical risks, and potential influence of concomitant antidiabetic medications","volume":"6","year":"2018","journal-title":"JACC Heart Fail"},{"issue":"21","key":"2021032622392042935_j_jaoa.2020.007_ref_018_w2aab3b7c33b1b6b1ab2b1c18Aa","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1016\/j.jacc.2017.04.014","article-title":"Novel diabetes drugs and the cardiovascular specialist","volume":"69","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"2021032622392042935_j_jaoa.2020.007_ref_019_w2aab3b7c33b1b6b1ab2b1c19Aa","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.jacc.2018.06.040","article-title":"Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC State-of-the-Art review","volume":"72","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"2021032622392042935_j_jaoa.2020.007_ref_020_w2aab3b7c33b1b6b1ab2b1c20Aa","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1161\/01.CIR.0000072767.89944.6E","article-title":"Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study","volume":"107","year":"2003","journal-title":"Circulation"},{"issue":"8","key":"2021032622392042935_j_jaoa.2020.007_ref_021_w2aab3b7c33b1b6b1ab2b1c21Aa","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1093\/eurjhf\/hft041","article-title":"Risk assessment for incident heart failure in individuals with atrial fibrillation","volume":"15","year":"2013","journal-title":"Eur J Heart Fail"},{"issue":"23","key":"2021032622392042935_j_jaoa.2020.007_ref_022_w2aab3b7c33b1b6b1ab2b1c22Aa","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1016\/j.jacc.2018.03.519","article-title":"Progression of device-related subclinical atrial fibrillation and the risk of heart failure","volume":"71","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2021032622392042935_j_jaoa.2020.007_ref_023_w2aab3b7c33b1b6b1ab2b1c23Aa","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1707855","article-title":"Catheter ablation for atrial fibrillation with heart failure","volume":"378","year":"2018","journal-title":"N Engl J Med"},{"issue":"139","key":"2021032622392042935_j_jaoa.2020.007_ref_024_w2aab3b7c33b1b6b1ab2b1c24Aa","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","article-title":"AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons","volume":"2019","year":"2019","journal-title":"Circulation"},{"issue":"27","key":"2021032622392042935_j_jaoa.2020.007_ref_025_w2aab3b7c33b1b6b1ab2b1c25Aa","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology developed with the special contribution of the Heart Failure Association","volume":"37","year":"2016","journal-title":"Eur Heart J"},{"issue":"72","key":"2021032622392042935_j_jaoa.2020.007_ref_026_w2aab3b7c33b1b6b1ab2b1c26Aa","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/j.jacc.2017.10.053","article-title":"AHA\/ACC\/HRS guideline for management of patient with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College\/American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm Society","volume":"2018","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"2021032622392042935_j_jaoa.2020.007_ref_027_w2aab3b7c33b1b6b1ab2b1c27Aa","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMoa1608029","article-title":"Defibrillator implantation in patients with nonischemic systolic heart failure","volume":"375","year":"2016","journal-title":"N Engl J Med"},{"issue":"13","key":"2021032622392042935_j_jaoa.2020.007_ref_028_w2aab3b7c33b1b6b1ab2b1c28Aa","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1056\/NEJMe1609826","article-title":"The ICD in heart failure\u2014time for a rethink?","volume":"375","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"2021032622392042935_j_jaoa.2020.007_ref_029_w2aab3b7c33b1b6b1ab2b1c29Aa","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.hrthm.2017.11.012","article-title":"Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices","volume":"15","year":"2018","journal-title":"Heart Rhythm"},{"issue":"5","key":"2021032622392042935_j_jaoa.2020.007_ref_030_w2aab3b7c33b1b6b1ab2b1c30Aa","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.jacc.2016.05.060","article-title":"Underutilization of coronary artery disease testing among patients hospitalized with new-onset heart failure","volume":"68","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"2021032622392042935_j_jaoa.2020.007_ref_031_w2aab3b7c33b1b6b1ab2b1c31Aa","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1056\/NEJMoa1100356","article-title":"Coronary artery bypass surgery in patients with left ventricular dysfunction","volume":"364","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"2021032622392042935_j_jaoa.2020.007_ref_032_w2aab3b7c33b1b6b1ab2b1c32Aa","doi-asserted-by":"publisher","first-page":"e003255","DOI":"10.1161\/CIRCHEARTFAILURE.116.003255","article-title":"Survival benefits of invasive versus conservative strategies in heart failure in patients with reduced ejection fraction and coronary artery disease: a meta-analysis","volume":"10","year":"2017","journal-title":"Circ Heart Failure"},{"issue":"25","key":"2021032622392042935_j_jaoa.2020.007_ref_033_w2aab3b7c33b1b6b1ab2b1c33Aa","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.1161\/01.CIR.0000133321.00456.00","article-title":"Preventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association","volume":"109","year":"2004","journal-title":"Circulation"},{"issue":"24","key":"2021032622392042935_j_jaoa.2020.007_ref_034_w2aab3b7c33b1b6b1ab2b1c34Aa","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1161\/CIRCULATIONAHA.117.031912","article-title":"Cigarette smoking and incident heart failure: insights from the Jackson Heart Study","volume":"137","year":"2018","journal-title":"Circulation"},{"issue":"1","key":"2021032622392042935_j_jaoa.2020.007_ref_035_w2aab3b7c33b1b6b1ab2b1c35Aa","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jchf.2015.08.007","article-title":"Impact of dietary sodium restriction on heart failure outcomes","volume":"4","year":"2016","journal-title":"JACC Heart Fail"},{"issue":"4","key":"2021032622392042935_j_jaoa.2020.007_ref_036_w2aab3b7c33b1b6b1ab2b1c36Aa","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/s0735-1097(01)01802-2","article-title":"The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: the obesity paradox?","volume":"39","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2021032622392042935_j_jaoa.2020.007_ref_037_w2aab3b7c33b1b6b1ab2b1c37Aa","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jchf.2015.11.010","article-title":"Complementary role of arm circumference to body mass index in risk stratification in heart failure","volume":"4","year":"2016","journal-title":"JACC Heart Fail"},{"issue":"1","key":"2021032622392042935_j_jaoa.2020.007_ref_038_w2aab3b7c33b1b6b1ab2b1c38Aa","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1161\/CIRCULATIONAHA","article-title":"Body mass index and vigorous physical activity and the risk of heart failure among men","volume":"119","year":"2009","journal-title":"Circulation"},{"key":"2021032622392042935_j_jaoa.2020.007_ref_039_w2aab3b7c33b1b6b1ab2b1c39Aa","volume-title":"Physical Activity Guidelines Advisory Committee Scientific Report","author":"2018 Physical Activity Guidelines Advisory Committee","year":"2018"},{"issue":"17","key":"2021032622392042935_j_jaoa.2020.007_ref_040_w2aab3b7c33b1b6b1ab2b1c40Aa","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1161\/CIRCULATIONAHA","article-title":"Weight loss and heart failure: a nationwide study of gastric bypass surgery versus intensive lifestyle management","volume":"135","year":"2017","journal-title":"Circulation"},{"issue":"5","key":"2021032622392042935_j_jaoa.2020.007_ref_041_w2aab3b7c33b1b6b1ab2b1c41Aa","doi-asserted-by":"publisher","first-page":"e005126","DOI":"10.1161\/JAHA.116.005126","article-title":"Gastric bypass surgery produces a durable reduction in cardiovascular disease risk factors and reduces the long-term risks of congestive heart failure","volume":"6","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"2021032622392042935_j_jaoa.2020.007_ref_042_w2aab3b7c33b1b6b1ab2b1c42Aa","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/jama.2011.1914","article-title":"Bariatric surgery and long-term cardiovascular events","volume":"307","year":"2012","journal-title":"JAMA"},{"key":"2021032622392042935_j_jaoa.2020.007_ref_043_w2aab3b7c33b1b6b1ab2b1c43Aa","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.jacc.2015.12.016","article-title":"Bariatric surgery and emergency department visits and hospitalizations for heart failure exacerbation: population-based, self-controlled series","volume":"67","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"2021032622392042935_j_jaoa.2020.007_ref_044_w2aab3b7c33b1b6b1ab2b1c44Aa","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jacc.2018.06.034","article-title":"Cookbook medicine is the recipe for successfully managing patients with PAD","volume":"72","year":"2018","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Osteopathic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.7556\/jaoa.2020.007\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.7556\/jaoa.2020.007\/html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T22:39:31Z","timestamp":1616798371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.7556\/jaoa.2020.007\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,1]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2,1]]},"published-print":{"date-parts":[[2020,2,1]]}},"alternative-id":["10.7556\/jaoa.2020.007"],"URL":"https:\/\/doi.org\/10.7556\/jaoa.2020.007","relation":{},"ISSN":["2702-3648"],"issn-type":[{"value":"2702-3648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,1]]}}}